Abstract 953P
Background
Second-line treatment options for patients with unresectable hepatocellular carcinoma (uHCC) are limited. Monotherapy with regorafenib or tislelizumab (an anti-PD-1 antibody) has shown clinical benefit for uHCC in the second-line setting. The present study explored the safety and efficacy of the tislelizumab plus regorafenib as second-line therapy for uHCC.
Methods
This was a single-arm, investigator-initiated phase II trial. Patients with confirmed uHCC were enrolled to receive tislelizumab (200mg, q3w) plus regorafenib (80mg-160mg, daily, 3 weeks on/1 week off, every 4 weeks). The primary endpoint was safety and tolerability; Secondary endpoints included overall response rates (ORR), progression-free survival (PFS), and disease control rate (DCR) per mRECIST.
Results
A total of 28 patients were enrolled with median age of 59 years (range: 40-76) and 96% were men. Most common etiology of HCC was hepatitis B (n=26, 93%). 54% of patients were Barcelona Clinic Liver Cancer stage C. 67.9% of patients received prior treatment with tyrosine kinase inhibitors (TKIs; sorafenib [50%] or lenvatinib [17.9%]), and 21.4% received TKIs plus PD-1 antibody. ORR was 28.6% and DCR was 71.4%, with 3 pts having CR, 5 PR, and 12 SD. At the data cut-off date, the median PFS of the 28 pts was 6.4 months (95%Cl 90%, NA)), and the median OS was not reached. The most common treatment-related adverse events at any grade were rash (6/28;21%), hypertension (9/28;32%), hand-foot syndrome (18/28;64%) and fatigue (7/28;25%), which were mostly grade 1 or 2 in severity.
Conclusions
This study indicated that tislelizumab plus regorafenib is an effective and well-tolerated therapeutic option for patients with uHCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xuetao Shi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
842P - Multicenter real-world study of newly diagnosed advanced-stage extranodal natural killer/T cell lymphoma (ENKTL): Proposal for intensive therapy
Presenter: Yu-Ce Wei
Session: Poster session 18
844P - Progression -free survival prediction of multiple myeloma patients in five European countries using machine learning models
Presenter: Maria Luisa Pleguezuelo Witte
Session: Poster session 18
845P - A machine learning based clinical platform for cancer subtyping and data integration in hematological malignancies
Presenter: Michelle Tang
Session: Poster session 18
846P - Artificial intelligence-driven identification of onco-hematology patients who may develop severe COVID-19
Presenter: Souad Assaad
Session: Poster session 18
847P - Fatal infections among leukemia patients
Presenter: Huijie Zhou
Session: Poster session 18
848P - Mortality after rasburicase vs allopurinol anti-hyperuricemia monotherapy in patients with liquid tumors
Presenter: Mitchell Cairo
Session: Poster session 18
849P - Long non-coding RNA signatures and their role in the progression of childhood T cell acute lymphoblastic leukemia
Presenter: Pankaj Sharma
Session: Poster session 18
850P - A zebrafish model of MYC-driven acute myeloid leukemia reveals that neutrophil resistance to oncogenic transformation depends on their ability to promote PP2A-mediated MYC proteasomal degradation
Presenter: Anna Maria Luciano
Session: Poster session 18
851P - Characterization of a zebrafish model of MYC-driven acute myeloid leukemia
Presenter: Anna Maria Luciano
Session: Poster session 18
852P - c-MAF-driven metabolic reprogramming mediates H3K27 hyperacetylation to regulate super enhancer-associated genes
Presenter: Phyllis SY Chong
Session: Poster session 18